Allakos Inc. (ALLK)
0.32
-0.00 (-0.40%)
At close: Apr 03, 2025, 3:59 PM
0.32
-0.50%
After-hours: Apr 03, 2025, 05:07 PM EDT
-0.40% (1D)
| Bid | 0.32 |
| Market Cap | 28.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.3 |
| PE Ratio (ttm) | -0.25 |
| Forward PE | -0.41 |
| Analyst | Hold |
| Ask | 0.33 |
| Volume | 2,907,144 |
| Avg. Volume (20D) | 2,792,776 |
| Open | 0.32 |
| Previous Close | 0.32 |
| Day's Range | 0.32 - 0.32 |
| 52-Week Range | 0.22 - 1.56 |
| Beta | 0.71 |
About ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 19, 2018
Employees 131
Stock Exchange NASDAQ
Ticker Symbol ALLK
Website https://www.allakos.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 524.80% from the latest price.
Stock Forecasts1 day ago
+48.06%
Allakos shares are trading higher after the compan...
Unlock content with
Pro Subscription
2 months ago
-80.47%
Allakos shares are trading lower after the company announced it will discontinue further development of AK006, reduce its workforce by 75%, and explore strategic alternatives.
